Drugs / CP-101,606
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00163085 | May 2005 → Jan 2006 | Parkinson disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00163059 | May 2004 → Dec 2005 | major depressive disorder | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-101,606 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00163085 ↗ |
| Known as | traxoprodil | “NR2B NMDA Antagonist CP-101,606 (traxoprodil)” NCT00163085 ↗1“NMDA Antagonist, CP-101,606 (traxoprodil)” NCT00163059 ↗ |
| Action | Inhibit | “NMDA antagonist” NCT00163059 ↗ |